These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23172644)

  • 1. SAR analysis and bioactive potentials of freshwater and terrestrial cyanobacterial compounds: a review.
    Nagarajan M; Maruthanayagam V; Sundararaman M
    J Appl Toxicol; 2013 May; 33(5):313-49. PubMed ID: 23172644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of pharmacological and toxicological potentials of marine cyanobacterial metabolites.
    Nagarajan M; Maruthanayagam V; Sundararaman M
    J Appl Toxicol; 2012 Mar; 32(3):153-85. PubMed ID: 21910132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic and peptidase inhibitory activities of selected non-hepatotoxic cyclic peptides from cyanobacteria.
    Bubik A; Sedmak B; Novinec M; Lenarcic B; Lah TT
    Biol Chem; 2008 Oct; 389(10):1339-46. PubMed ID: 18713022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelopathy in freshwater cyanobacteria.
    Leão PN; Vasconcelos MT; Vasconcelos VM
    Crit Rev Microbiol; 2009; 35(4):271-82. PubMed ID: 19863381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-ribosomal peptides produced by Brazilian cyanobacterial isolates with antimicrobial activity.
    Silva-Stenico ME; Silva CS; Lorenzi AS; Shishido TK; Etchegaray A; Lira SP; Moraes LA; Fiore MF
    Microbiol Res; 2011 Mar; 166(3):161-75. PubMed ID: 20630723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity of bioactive compound content across 71 genera of marine, freshwater, and terrestrial cyanobacteria.
    Huang IS; Pietrasiak N; Gobler CJ; Johansen JR; Burkholder JM; D'Antonio S; Zimba PV
    Harmful Algae; 2021 Nov; 109():102116. PubMed ID: 34815023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases.
    Liu Y; Zhang W; Li L; Salvador LA; Chen T; Chen W; Felsenstein KM; Ladd TB; Price AR; Golde TE; He J; Xu Y; Li Y; Luesch H
    J Med Chem; 2012 Dec; 55(23):10749-65. PubMed ID: 23181502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical agents from filamentous marine cyanobacteria.
    Tan LT
    Drug Discov Today; 2013 Sep; 18(17-18):863-71. PubMed ID: 23711931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyanobacterial bioactive molecules--an overview of their toxic properties.
    Jaiswal P; Singh PK; Prasanna R
    Can J Microbiol; 2008 Sep; 54(9):701-17. PubMed ID: 18772933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioactive natural products from marine cyanobacteria for drug discovery.
    Tan LT
    Phytochemistry; 2007 Apr; 68(7):954-79. PubMed ID: 17336349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro modulation of intracellular receptor signaling and cytotoxicity induced by extracts of cyanobacteria, complex water blooms and their fractions.
    Stěpánková T; Ambrožová L; Bláha L; Giesy JP; Hilscherová K
    Aquat Toxicol; 2011 Oct; 105(3-4):497-507. PubMed ID: 21903046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyanobacterial peptides as a tour de force in the chemical space of antiparasitic agents.
    Rivas L; Rojas V
    Arch Biochem Biophys; 2019 Mar; 664():24-39. PubMed ID: 30707942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemodiversity in freshwater and terrestrial cyanobacteria - a source for drug discovery.
    Chlipala GE; Mo S; Orjala J
    Curr Drug Targets; 2011 Oct; 12(11):1654-73. PubMed ID: 21561419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium Lyngbya confervoides.
    Matthew S; Ross C; Rocca JR; Paul VJ; Luesch H
    J Nat Prod; 2007 Jan; 70(1):124-7. PubMed ID: 17253864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of harmful cyanobacteria on the freshwater pathogenic free-living amoeba Acanthamoeba castellanii.
    Urrutia-Cordero P; Agha R; Cirés S; Lezcano MÁ; Sánchez-Contreras M; Waara KO; Utkilen H; Quesada A
    Aquat Toxicol; 2013 Apr; 130-131():9-17. PubMed ID: 23333903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seaweed Bioactive Compounds against Pathogens and Microalgae: Potential Uses on Pharmacology and Harmful Algae Bloom Control.
    Zerrifi SEA; El Khalloufi F; Oudra B; Vasconcelos V
    Mar Drugs; 2018 Feb; 16(2):. PubMed ID: 29425153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of tolerance to cyanobacterial protease inhibitors revealed by clonal differences in Daphnia magna.
    Schwarzenberger A; Kuster CJ; Von Elert E
    Mol Ecol; 2012 Oct; 21(19):4898-911. PubMed ID: 22943151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indole alkaloids from Fischerella inhibit vertebrate development in the zebrafish (Danio rerio) embryo model.
    Walton K; Gantar M; Gibbs PD; Schmale MC; Berry JP
    Toxins (Basel); 2014 Dec; 6(12):3568-81. PubMed ID: 25533520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical review of actually available chemical compounds for prevention and management of cyanobacterial blooms.
    Jančula D; Maršálek B
    Chemosphere; 2011 Nov; 85(9):1415-22. PubMed ID: 21925702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carriebowlinol, an antimicrobial tetrahydroquinolinol from an assemblage of marine cyanobacteria containing a novel taxon.
    Soares AR; Engene N; Gunasekera SP; Sneed JM; Paul VJ
    J Nat Prod; 2015 Mar; 78(3):534-8. PubMed ID: 25536090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.